-
Drug-Drug Interactions (DDI) amidst the Pandemic and Opportunities for Objective DDI Monitoring via Oral Fluid Testing
The Coronavirus Disease 19 (COVID-19) pandemic has introduced many different challenges to the world this year. Economic, technologic, and healthcare issues…
-
COVID-19 and Its Impact on Persons with Mental Illness and Substance Use
The COVID-19 pandemic has brought significant challenges to both healthcare systems and public health. Social distancing, disruption of healthcare services,…
-
Emerging Data on Novel Psychoactive Substances and Clinical Effects
Emerging Data on Novel Psychoactive Substances and Clinical Effects Aegis launched an extensive and industry-leading testing menu of Novel Psychoactive…
-
Designer Opioids and Benzodiazepines
Novel Psychoactive Substances (NPS) are a diverse group of synthetic substances created to mimic the effects of scheduled or illicit drugs which vary significantly…
-
Synthetic Cannabinoids and Synthetic Stimulants
Novel Psychoactive Substances (NPS) are a diverse group of synthetic substances created to mimic the effects of scheduled or illicit drugs; however, they…
-
Expansion of Oral Fluid Testing of Behavioral Health Drugs
Aegis’ oral fluid testing menu has been expanded to allow providers the option to test for many additional medications and/or illicit drugs. The enhancement…
-
Review of New InterAct Rx Analyte Positivity
In 2015, Aegis Sciences Corporation began to seek out a way to expand the clinical information that could be provided through definitive testing. With…
